دورية أكاديمية
أعرض في EDS

Detection Rate of Prostate Cancer in Repeat Biopsy after an Initial Negative Magnetic Resonance Imaging/Ultrasound-Guided Biopsy.

التفاصيل البيبلوغرافية
العنوان: Detection Rate of Prostate Cancer in Repeat Biopsy after an Initial Negative Magnetic Resonance Imaging/Ultrasound-Guided Biopsy.
المؤلفون: Görtz M; Department of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany.; Junior Clinical Cooperation Unit 'Multiparametric Methods for Early Detection of Prostate Cancer', German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Huber AK; Medical Faculty, Ruprecht-Karls University of Heidelberg, 69117 Heidelberg, Germany., Linz T; Medical Faculty, Ruprecht-Karls University of Heidelberg, 69117 Heidelberg, Germany., Schwab C; Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany., Stenzinger A; Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany., Goertz L; Department of Radiology, Medical Faculty and University Hospital, University of Cologne, 50939 Cologne, Germany., Bonekamp D; Divison of Radiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Schlemmer HP; Divison of Radiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany., Hohenfellner M; Department of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
المصدر: Diagnostics (Basel, Switzerland) [Diagnostics (Basel)] 2023 May 17; Vol. 13 (10). Date of Electronic Publication: 2023 May 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101658402 Publication Model: Electronic Cited Medium: Print ISSN: 2075-4418 (Print) Linking ISSN: 20754418 NLM ISO Abbreviation: Diagnostics (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG, [2011]-
مستخلص: A negative multiparametric magnetic resonance imaging (mpMRI)-guided prostate biopsy in patients with suspected prostate cancer (PC) results in clinical uncertainty, as the biopsy can be false negative. The clinical challenge is to determine the optimal follow-up and to select patients who will benefit from repeat biopsy. In this study, we evaluated the rate of significant PC (sPC, Gleason score ≥7) and PC detection in patients who received a follow-up mpMRI/ultrasound-guided biopsy for persistent PC suspicion after a negative mpMRI/ultrasound-guided biopsy. We identified 58 patients at our institution that underwent repeat targeted biopsy in case of PI-RADS lesions and systematic saturation biopsy between 2014 and 2022. At the initial biopsy, the median age was 59 years, and the median prostate specific antigen level was 6.7 ng/mL. Repeat biopsy after a median of 18 months detected sPC in 3/58 (5%) patients and Gleason score 6 PC in 11/58 (19%). Among 19 patients with a downgraded PI-RADS score at the follow-up mpMRI, none had sPC. In conclusion, men with an initial negative mpMRI/ultrasound-guided biopsy had a high likelihood of not harboring sPC at repeat biopsy (95%). Due to the small size of the study, further research is recommended.
References: Eur Urol. 2019 Apr;75(4):570-578. (PMID: 30477981)
BJU Int. 2014 Sep;114(3):384-8. (PMID: 24612341)
Eur Urol Focus. 2023 Apr 6;:. (PMID: 37031096)
Eur Urol. 2017 Dec;72(6):888-896. (PMID: 28400169)
Cancers (Basel). 2022 Feb 10;14(4):. (PMID: 35205634)
J Urol. 2020 Dec;204(6):1180-1186. (PMID: 32614257)
J Urol. 2013 Aug;190(2):496-501. (PMID: 23466239)
N Engl J Med. 2018 May 10;378(19):1767-1777. (PMID: 29552975)
Biomark Med. 2014;8(9):1143-50. (PMID: 25402584)
JAMA. 2015 Jan 27;313(4):390-7. (PMID: 25626035)
Eur Urol Focus. 2021 Mar;7(2):325-331. (PMID: 31839564)
Radiology. 2018 May;287(2):534-542. (PMID: 29361246)
Eur Urol. 2016 Jan;69(1):16-40. (PMID: 26427566)
J Urol. 2013 Mar;189(3):1110-6. (PMID: 22999998)
J Magn Reson Imaging. 2017 Feb;45(2):579-585. (PMID: 27391860)
Eur Urol. 2010 Jan;57(1):79-85. (PMID: 19733959)
Clin Imaging. 2017 May - Jun;43:64-68. (PMID: 28196759)
Invest Radiol. 2021 Dec 1;56(12):799-808. (PMID: 34049336)
In Vivo. 2019 May-Jun;33(3):897-901. (PMID: 31028214)
Clin Epigenetics. 2019 Oct 30;11(1):152. (PMID: 31666119)
Nat Rev Urol. 2016 Apr;13(4):205-15. (PMID: 26954332)
Lancet. 2014 Dec 6;384(9959):2027-35. (PMID: 25108889)
Lancet. 2017 Feb 25;389(10071):815-822. (PMID: 28110982)
Eur Radiol. 2016 Jun;26(6):1606-12. (PMID: 26396111)
Cochrane Database Syst Rev. 2019 Apr 25;4:CD012663. (PMID: 31022301)
CA Cancer J Clin. 2022 Jan;72(1):7-33. (PMID: 35020204)
Eur Radiol. 2012 Apr;22(4):746-57. (PMID: 22322308)
Eur Radiol. 2017 Jun;27(6):2259-2266. (PMID: 27778089)
Curr Opin Urol. 2016 Sep;26(5):481-7. (PMID: 27314568)
Eur Urol. 2002 Aug;42(2):93-103. (PMID: 12160578)
Eur Urol Focus. 2015 Sep;1(2):127-136. (PMID: 28723423)
J Urol. 2014 Oct;192(4):1081-7. (PMID: 24747657)
Lancet Oncol. 2019 Jan;20(1):100-109. (PMID: 30470502)
Eur Urol. 2019 Mar;75(3):385-396. (PMID: 29908876)
Eur Urol. 2022 Nov;82(5):452-457. (PMID: 35985901)
Cancers (Basel). 2022 Dec 11;14(24):. (PMID: 36551580)
Radiology. 2018 Oct;289(1):128-137. (PMID: 30063191)
Eur Urol. 2016 Nov;70(5):846-853. (PMID: 26810346)
BJU Int. 2013 Sep;112(5):568-77. (PMID: 23773772)
Nat Rev Urol. 2022 Sep;19(9):562-572. (PMID: 35974245)
Clin Cancer Res. 2005 Dec 1;11(23):8321-5. (PMID: 16322291)
J Urol. 2021 Mar;205(3):748-754. (PMID: 33080145)
Urol Oncol. 2022 Mar;40(3):103.e17-103.e24. (PMID: 34688534)
Eur Urol. 2019 Sep;76(3):340-351. (PMID: 30898406)
BJU Int. 2020 Feb;125(2):260-269. (PMID: 31306539)
Korean J Radiol. 2018 Jul-Aug;19(4):733-741. (PMID: 29962879)
J Urol. 2009 Apr;181(4):1678-85. (PMID: 19233404)
Cancer. 2014 Sep 15;120(18):2876-82. (PMID: 24917122)
Eur Urol Focus. 2021 Nov;7(6):1300-1307. (PMID: 32660838)
Eur Urol. 2013 Dec;64(6):876-92. (PMID: 23787356)
J Urol. 1998 Mar;159(3):920-4. (PMID: 9474183)
Cancer. 2011 Mar 15;117(6):1123-35. (PMID: 20960523)
Eur Urol. 2012 Nov;62(5):745-52. (PMID: 22704366)
J Urol. 2019 Dec;202(6):1159-1165. (PMID: 31188731)
J Mol Diagn. 2017 Jan;19(1):107-114. (PMID: 27939865)
Eur Urol. 2019 Jul;76(1):18-23. (PMID: 30685078)
Am J Surg Pathol. 2005 Sep;29(9):1228-42. (PMID: 16096414)
Eur Urol Oncol. 2021 Oct;4(5):697-713. (PMID: 33358543)
Eur Urol Oncol. 2022 Feb;5(1):54-60. (PMID: 34580053)
معلومات مُعتمدة: Dieter Morszeck Foundation
فهرسة مساهمة: Keywords: MRI/TRUS fusion biopsy; PI-RADS; magnetic resonance imaging; prostate cancer; prostate-specific antigen
تواريخ الأحداث: Date Created: 20230527 Latest Revision: 20230530
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10217194
DOI: 10.3390/diagnostics13101761
PMID: 37238245
قاعدة البيانات: MEDLINE
الوصف
تدمد:2075-4418
DOI:10.3390/diagnostics13101761